# US 2021/0275464 A1 · Biomembrane-covered nanoparticles (bionps) for delivering active agents to stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275464 A1
- Document ID: US20210275464A1
- Status: Published application
- Kind: A1
- Application number: 17/327,932
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2018-11-28
- Assignees: University of Delaware
- Inventors: Eleftherios T. Papoutsakis; Emily Day; Erica Winter; Jenna Harris; Chen-Yuan Kao; Samik Das
- Web page: https://patentgrep.com/patent/US20210275464A1

## CPC

- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- B01J 13/04: by physical processes, e.g. drying, spraying
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- B01J 13/22: Coating
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present invention provides bio-nanoparticles (BioNPs) for delivering an active agent into hematopoietic stem & progenitor cells (HSPCs). Each BioNP comprises a core and a biological membrane covering the core, which comprises the active agent and a polymer. The biological membrane comprises a phospholipid bilayer and one or more surface proteins of a megakaryocyte (Mk). The active agent remains active after being delivered into the HSPC. Also provided are methods for preparing the BioNPs and uses of the BioNPs for targeted delivery of an active agent into HSPCs and/or treating or preventing a disease or condition in a subject in need thereof.

## Claims

### Claim 1

A bio-nanoparticle for delivering an active agent into a hematopoietic stem & progenitor cell (HSPC), comprising a core and a biological membrane covering the core, wherein the core comprises the active agent and a polymer, wherein the biological membrane comprises a phospholipid bilayer and one or more surface proteins of a megakaryocyte (Mk), and wherein the active agent remains active after being delivered into the HSPC.

### Claim 2 (depends on 1)

The bio-nanoparticle of claim 1, wherein the biological membrane is adhered to the core by an electrostatic interaction.

### Claim 3 (depends on 1)

The bio-nanoparticle of claim 1, wherein the biological membrane is prepared from a megakaryocyte (Mk), megakaryocytic microparticle (MkMP) or megakaryocytic extracellular vesicle.

### Claim 4 (depends on 3)

The bio-nanoparticle of claim 3, wherein the megakaryocyte (Mk), megakaryocytic microparticle or megakaryocytic extracellular vesicle is prepared from a hematopoietic stem & progenitor cell (HSPC) or a human megakaryocyte cell line.

### Claim 5 (depends on 3)

The bio-nanoparticle of claim 3, wherein the biological membrane is prepared from a megakaryocyte (Mk) and the bio-nanoparticle lacks a cytosolic, nuclear or mitochondrial component of the Mk.

### Claim 6 (depends on 1)

The bio-nanoparticle of claim 1, wherein the one or more surface proteins are selected from the group consisting of CD62P, VLA-4 (CD49d), CD41, CD150, CXCR4, thrombopoietin (TPO) receptor, c-kit, CD34, CD105 (endoglin), CD31 (9PECAM-1), JAM-A, Tie-2, KDR (VEGF receptor 2) and a combination thereof.

### Claim 7 (depends on 1)

The bio-nanoparticle of claim 1, wherein the polymer is poly(lactic-co-glycolic acid) (PLGA).

### Claim 8 (depends on 1)

The bio-nanoparticle of claim 1, wherein the active agent is hydrophobic and the core is prepared from a single-emulsion or double-emulsion.

### Claim 9 (depends on 1)

The bio-nanoparticle of claim 1, wherein the active agent is selected from the group consisting of an imaging agent, a therapeutic agent, and a combination thereof, wherein the imaging agent is selected from the group consisting of fluorophores, MRI contrast agents, CT contrast agents, ultrasound contrast agents, and combinations thereof, wherein the therapeutic agent is a nucleic acid molecule selected from the group consisting of siRNA, miRNA, DNA, and a combination thereof, wherein the DNA is a single-stranded DNA, and wherein the therapeutic agent is selected from the group consisting of chemotherapeutics, HSPC mobilizing agents, and a combination thereof.

### Claim 10

A method for preparing a bio-nanoparticle for delivering an active agent into a hematopoietic stem & progenitor cell (HSPC), comprising coating a core with a biological membrane at an effective weight ratio for forming a bio-nanoparticle, wherein the core comprises the active agent and a polymer, wherein the biological membrane comprises two layers of phospholipids and one or more surface proteins of a megakaryocyte (Mk), and wherein the active agent remains active after being delivered into the HSPC.

### Claim 11 (depends on 10)

The method of claim 10, further comprising preparing the biological membrane from a megakaryocyte (Mk), megakaryocytic microparticle or megakaryocytic extracellular vesicle.

### Claim 12 (depends on 11)

The method of claim 11, further comprising preparing the megakaryocyte (Mk), megakaryocytic microparticle or megakaryocytic extracellular vesicle from a hematopoietic stem & progenitor cell (HSPC) or a human megakaryocyte cell line.

### Claim 13 (depends on 10)

The method of claim 10, further comprising preparing the biological membrane from a megakaryocyte (Mk) after one or more components of the Mk are removed from the Mk, wherein the one or more components are selected from the group consisting of cytosolic, nuclear and mitochondrial components.

### Claim 14 (depends on 10)

The method of claim 10, further comprising adhering the biological membrane to the core by an electrostatic interaction.

### Claim 15 (depends on 10)

The method of claim 10, wherein the one or more surface proteins are selected from the group consisting of CD62P, VLA-4 (CD49d), CD41, CD150, CXCR4,thrombopoietin (TPO) receptor, c-kit, CD34, CD105 (endoglin), CD31 (9PECAM-1), JAM-A, Tie-2, KDR (VEGF receptor 2) and a combination thereof.

### Claim 16 (depends on 10)

The method of claim 10, wherein the polymer is poly(lactic-co-glycolic acid) (PLGA).

### Claim 17 (depends on 10)

The method of claim 10, wherein the active agent is hydrophobic, further comprising preparing the core from a single-emulsion or double emulsion.

### Claim 18 (depends on 10)

The method of claim 10, wherein the active agent is selected from the group consisting of an imaging agent, a therapeutic agent, and a combination thereof, wherein the imaging agent is selected from the group consisting of fluorophores, MRI contrast agents, CT contrast agents, ultrasound contrast agents, and a combination thereof, wherein the therapeutic agent is a nucleic acid molecule selected from the group consisting of siRNA, miRNA, DNA, and a combination thereof, wherein the DNA is a single-stranded DNA, wherein the therapeutic agent is selected from the group consisting of chemotherapeutics, HSPC mobilizing agents, and a combination thereof, and wherein the therapeutic agent is a chemotherapeutic.

### Claim 19 (depends on 1)

A method for treating a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of the bio-nanoparticles of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the disease or condition is selected from the group consisting of bone marrow failure disorder, leukemia, lymphoma, multiple myeloma, aplastic anemia, sickle cell disease, thalassemia, autoimmune disorders, HIV, multiple sclerosis, myeloproliferative disorder, myelodysplastic syndrome, and other forms of cancer.
